The MarketReader Minute
💊 Morphic Holding Inc Surged on Eli Lilly's $3.2 Billion Acquisition Offer, Biogen Influenced by Pending Lawsuits| Biotech Sector Insights
Eli Lilly acquiring Morphic Holding at a significant premium price point of $3.2 billion cash deal with positive clinical data released by IDEAYA Biosciences Inc led to favorable market sentiment around these companies.